Substituted tetralins as selective estrogen receptor-β agonists
US8093302B2 · kind B2 · utility
1Cited by
5References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2006 |
| Grant date | Jan 10, 2012 |
| Priority date | — |
| Expiry date | Oct 22, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/26
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to novel tetralin ER-β agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-β mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.